April 2009 Volume 43 Number 8, pp 593 - 668
---------------------------------------------------------------------
This alert is sponsored by Miltenyi Biotec
The CliniMACS Cell Selection System, based on MACS Technology, enables
the operator to perform clinical-scale magnetic separation of target
cells or depletion of unwanted cells.
http://links.ealert.nature.com/ctt?kn=62&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
http://links.ealert.nature.com/ctt?kn=5&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
---------------------------------------------------------------------
Nature Collections Cancer
This week, Nature updates the Nature Collection on Cancer with a
series of research papers and review material on some of the recent
advances in cancer research.
Access selected content from the updated collection free online for
6 months at:
http://links.ealert.nature.com/ctt?kn=12&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
Nature Collections Cancer is produced with support from Cephalon,
Genentech, Boehringer Ingelheim and Asterand
---------------------------------------------------------------------
A combined print and online personal subscription to this journal
gives you your own print copy and access to the entire website
including all back issues. Purchasing a subscription is easy; use
our online order form at
http://links.ealert.nature.com/ctt?kn=24&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
to start your subscription today.
----------------------
EDITORIAL
----------------------
Optimal mobilization method and CD34+ dose calculation for autologous
PBSC transplant in myeloma patients: two important unresolved questions
A Alegre
http://links.ealert.nature.com/ctt?kn=69&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
----------------------
REVIEW
----------------------
The evolution of hematopoietic SCT in myelodysplastic syndrome
T Kindwall-Keller and L M Isola
Abstract: http://links.ealert.nature.com/ctt?kn=74&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=48&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
----------------------
ORIGINAL ARTICLES
----------------------
Busulfex (i.v. BU) and CY regimen before SCT: Japanese-targeted phase
II pharmacokinetics combined study
S-W Kim, S-i Mori, R Tanosaki, T Fukuda, M Kami, H Sakamaki, T Yamashita,
Y Kodera, S Terakura, S Taniguchi, S Miyakoshi, N Usui, S Yano, Y Kawano,
Y Nagatoshi, M Harada, Y Morishima, S Okamoto, A M Saito, Y Ohashi,
R Ueda and Y Takaue
Abstract: http://links.ealert.nature.com/ctt?kn=31&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=26&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
Comparison of high-dose CY and growth factor with growth factor alone
for mobilization of stem cells for transplantation in patients with
multiple myeloma
M A Gertz, S K Kumar, M Q Lacy, A Dispenzieri, S R Hayman, F K Buadi,
D Dingli, D A Gastineau, J L Winters and M R Litzow
Abstract: http://links.ealert.nature.com/ctt?kn=68&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=75&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
Haematopoietic repopulating activity in human cord blood CD133+ quiescent
cells
S A Boxall, G P Cook, D Pearce, D Bonnet, Y M El-Sherbiny, M P Blundell,
S J Howe, J P Leek, A F Markham and E A de Wynter
Abstract: http://links.ealert.nature.com/ctt?kn=58&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=11&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
Height growth during adolescence and final height after haematopoietic
SCT for childhood acute leukaemia: the impact of a conditioning regimen
with BU or TBI
F Bernard, P Bordigoni, M-C Simeoni, V Barlogis, A Contet, A Loundou,
I Thuret, B Leheup, H Chambost, B Play, P Auquier and G Michel
Abstract: http://links.ealert.nature.com/ctt?kn=27&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=9&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
Prophylaxis regimens for GVHD: systematic review and meta-analysis
R Ram, A Gafter-Gvili, M Yeshurun, M Paul, P Raanani and O Shpilberg
Abstract: http://links.ealert.nature.com/ctt?kn=38&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=43&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
----------------------
LETTERS TO THE EDITOR
----------------------
Outcomes of transplantation of unrelated cord blood in children with
malignant and non-malignant diseases: an Utrecht-Prague collaborative
study
J J Boelens, M Bierings, M Tilanus, J Lie and P Sedlacek
http://links.ealert.nature.com/ctt?kn=32&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
Outcome of allo-SCT for chronic myelomonocytic leukemia
S Ocheni, N Kroger, T Zabelina, A R Zander and U Bacher
http://links.ealert.nature.com/ctt?kn=21&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
Acute thyrotoxicosis after SCT
S De Waele, A Van den Bruel, D Selleslag, I Van Den Berghe and
B Decallonne
http://links.ealert.nature.com/ctt?kn=53&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
Palifermin dose should be adjusted to different therapy regimens
M P M Verhagen, M J Wondergem and O Visser
http://links.ealert.nature.com/ctt?kn=71&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
Mycobacterium tuberculosis infection: a rare late complication after
cord blood hematopoietic SCT
R A De Assis, F R Kerbauy, M Rodrigues, F S Seguro, L F C Aranha,
L Fayad, E J Shpall, M de Lima and N Hamerschlak
http://links.ealert.nature.com/ctt?kn=30&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
---------------------------------------------------------------------
Announcing an open access option in British Journal of Cancer.
An open access option is now available to all authors of original
research papers that are accepted for publication in BJC.
BJC OPEN articles will be freely accessible to all readers
immediately on publication.
Learn more about BJC OPEN by visiting BJC online at
http://links.ealert.nature.com/ctt?kn=6&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0.
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to receive it.
You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=28&m=32894030&r=MTc1NjE0NTQ4OQS2&b=2&j=NDg1MzcxODQS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne - San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
© Copyright 2009 Nature Publishing Group
=====================================================================
